Pub Date : 2025-12-12DOI: 10.1007/s00259-025-07659-4
Mitchell Chen,Susan J Copley,Yidong Han,Mubarik A Arshad,Patrizia Viola,Kristofer Linton-Reid,Tina Stoycheva,Gary J R Cook,David Landau,Sue Chua,Richard O'Connor,Jeannette Dickson,Danielle Power,Andrea G Rockall,Tara D Barwick,Eric O Aboagye
PURPOSEAccurate prognostication is crucial for guiding personalised treatment strategies in non-small cell lung cancer (NSCLC). While radiomics offers promise, few features are derived from cancer models with causal justification to support their biological validity. This study evaluated the prognostic utility of normalised hotspot-to-centroid distance (NHOC), a recently proposed [18F]FDG PET imaging metric derived from a cancer evolutionary model, and its integration with PET/CT radiomics and clinical features to form a composite signature, non-invasive lung cancer evolution vector (nLCEV).METHODSA retrospective, multi-centre study was conducted using pre-treatment [18F]FDG PET/CT scans from 285 NSCLC patients (mean age: 67.7 ± 10.1 years; male:female = 171:114, International Association for the Study of Lung Cancer stage: T1/2/3/4/unknown = 61/118/53/52/1, N0/1/2/3/unknown = 133/46/71/34/1, M0/1/unknown = 222/62/1) from Imperial College Healthcare NHS Trust as the discovery cohort. External validation cohorts included patients from King's College (n = 53), Royal Marsden (n = 63), Mount Vernon (n = 61), and Nottingham University (n = 38) hospitals. NHOC was evaluated for 3-year overall survival prediction and combined with a multi-regional PET/CT radiomics predictive vector (RPV) and disease stage to develop nLCEV.RESULTSNHOC and RPV demonstrated independent prognostic value (hazard ratio (HR) [95% confidence interval]: 2.52 [1.60-3.98] and 2.68 [2.13-3.38], respectively). nLCEV achieved an area under the receiver operating characteristic curve of 0.76 [0.60-0.92] and stratified patients into high- and low-risk groups across all validation cohorts with significant HR: KCL 3.27 [1.31, 8.16], Marsden 2.21 [1.02, 4.78], Mount Vernon 2.60 [1.42, 4.76], and Nottingham 4.14 [1.44, 11.90] (all p < 0.05).CONCLUSIONNHOC enhances NSCLC patient survival prediction, and when integrated with PET-CT radiomics and disease stage, offers a robust, non-invasive approach to disease prognostication.
{"title":"An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomics.","authors":"Mitchell Chen,Susan J Copley,Yidong Han,Mubarik A Arshad,Patrizia Viola,Kristofer Linton-Reid,Tina Stoycheva,Gary J R Cook,David Landau,Sue Chua,Richard O'Connor,Jeannette Dickson,Danielle Power,Andrea G Rockall,Tara D Barwick,Eric O Aboagye","doi":"10.1007/s00259-025-07659-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07659-4","url":null,"abstract":"PURPOSEAccurate prognostication is crucial for guiding personalised treatment strategies in non-small cell lung cancer (NSCLC). While radiomics offers promise, few features are derived from cancer models with causal justification to support their biological validity. This study evaluated the prognostic utility of normalised hotspot-to-centroid distance (NHOC), a recently proposed [18F]FDG PET imaging metric derived from a cancer evolutionary model, and its integration with PET/CT radiomics and clinical features to form a composite signature, non-invasive lung cancer evolution vector (nLCEV).METHODSA retrospective, multi-centre study was conducted using pre-treatment [18F]FDG PET/CT scans from 285 NSCLC patients (mean age: 67.7 ± 10.1 years; male:female = 171:114, International Association for the Study of Lung Cancer stage: T1/2/3/4/unknown = 61/118/53/52/1, N0/1/2/3/unknown = 133/46/71/34/1, M0/1/unknown = 222/62/1) from Imperial College Healthcare NHS Trust as the discovery cohort. External validation cohorts included patients from King's College (n = 53), Royal Marsden (n = 63), Mount Vernon (n = 61), and Nottingham University (n = 38) hospitals. NHOC was evaluated for 3-year overall survival prediction and combined with a multi-regional PET/CT radiomics predictive vector (RPV) and disease stage to develop nLCEV.RESULTSNHOC and RPV demonstrated independent prognostic value (hazard ratio (HR) [95% confidence interval]: 2.52 [1.60-3.98] and 2.68 [2.13-3.38], respectively). nLCEV achieved an area under the receiver operating characteristic curve of 0.76 [0.60-0.92] and stratified patients into high- and low-risk groups across all validation cohorts with significant HR: KCL 3.27 [1.31, 8.16], Marsden 2.21 [1.02, 4.78], Mount Vernon 2.60 [1.42, 4.76], and Nottingham 4.14 [1.44, 11.90] (all p < 0.05).CONCLUSIONNHOC enhances NSCLC patient survival prediction, and when integrated with PET-CT radiomics and disease stage, offers a robust, non-invasive approach to disease prognostication.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1007/s00259-025-07691-4
Mark G MacAskill,Victoria J M Reid,Carlos J Alcaide-Corral,Timaeus E F Morgan,Lachlan Waddell,Adrian J W Thomson,Takeshi Fujisawa,Nicholas L Mills,Judit A Marti,Dominic Kurian,Thomas M Wishart,Ana Clara Juan De Albuquerque,Ernest Chui,Agne Knyzeliene,Viktoria Balogh,Catriona Wimberley,Marc R Dweck,David E Newby,Christophe Lucatelli,Sally L Pimlott,Andrew Sutherland,Adriana A S Tavares
PURPOSEInflammation affects cardiac remodelling following myocardial infarction (MI), and can be imaged using Positron Emission Tomography (PET) targeting the 18 kDa translocator protein (TSPO). We utilised a rat reperfusion MI model to assess whether longitudinal [18F]LW223 could accurately measure macrophage-driven inflammation using outcome measures amenable to clinical translation, in addition to assessing the prognostic potential of [18F]LW223 for cardiac dysfunction.METHODSAdult male Sprague-Dawley rats underwent coronary artery ligation and reperfusion to induce MI. [18F]LW223 PET/Computed Tomography was performed longitudinally on day 2, 7, 14 and 28 post-MI. On day 28, cardiac function was assessed by ultrasound. Naïve and sham rat controls were compared to the MI cohort. A separate cohort of rats were produced for histological validation and proteomic analysis.RESULTS[18F]LW223 standard uptake value corrected for myocardial blood flow (SUVMBF) was highest within the MI cohort and localised to the infarct. This peaked at day 2 and remained elevated versus naïve and sham controls out to day 28. These patterns were validated by histology, revealing that the majority of TSPO expressing cells within the infarct at day 2 were also CD68+ (55.2%). Proteomics confirmed upregulation of several proinflammatory processes at day 2, and a commonality in upregulated inflammatory response proteins at both day 2 and day 28, indicting ongoing inflammation. Infarct [18F]LW223 uptake at day 2 correlated with infarct size (p = 0.0016, R2 = 0.73) and cardiac dysfunction at day 28 (p = 0.0020, R2 = 0.82).CONCLUSION[18F]LW223 identifies a persistent and predominantly macrophage-driven inflammatory response with early [18F]LW223 infarct binding associated with later cardiac dysfunction.
{"title":"Longitudinal [18F]LW223 PET imaging of macrophage-driven inflammation following myocardial infarction in a rat model: implications for left ventricular remodelling.","authors":"Mark G MacAskill,Victoria J M Reid,Carlos J Alcaide-Corral,Timaeus E F Morgan,Lachlan Waddell,Adrian J W Thomson,Takeshi Fujisawa,Nicholas L Mills,Judit A Marti,Dominic Kurian,Thomas M Wishart,Ana Clara Juan De Albuquerque,Ernest Chui,Agne Knyzeliene,Viktoria Balogh,Catriona Wimberley,Marc R Dweck,David E Newby,Christophe Lucatelli,Sally L Pimlott,Andrew Sutherland,Adriana A S Tavares","doi":"10.1007/s00259-025-07691-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07691-4","url":null,"abstract":"PURPOSEInflammation affects cardiac remodelling following myocardial infarction (MI), and can be imaged using Positron Emission Tomography (PET) targeting the 18 kDa translocator protein (TSPO). We utilised a rat reperfusion MI model to assess whether longitudinal [18F]LW223 could accurately measure macrophage-driven inflammation using outcome measures amenable to clinical translation, in addition to assessing the prognostic potential of [18F]LW223 for cardiac dysfunction.METHODSAdult male Sprague-Dawley rats underwent coronary artery ligation and reperfusion to induce MI. [18F]LW223 PET/Computed Tomography was performed longitudinally on day 2, 7, 14 and 28 post-MI. On day 28, cardiac function was assessed by ultrasound. Naïve and sham rat controls were compared to the MI cohort. A separate cohort of rats were produced for histological validation and proteomic analysis.RESULTS[18F]LW223 standard uptake value corrected for myocardial blood flow (SUVMBF) was highest within the MI cohort and localised to the infarct. This peaked at day 2 and remained elevated versus naïve and sham controls out to day 28. These patterns were validated by histology, revealing that the majority of TSPO expressing cells within the infarct at day 2 were also CD68+ (55.2%). Proteomics confirmed upregulation of several proinflammatory processes at day 2, and a commonality in upregulated inflammatory response proteins at both day 2 and day 28, indicting ongoing inflammation. Infarct [18F]LW223 uptake at day 2 correlated with infarct size (p = 0.0016, R2 = 0.73) and cardiac dysfunction at day 28 (p = 0.0020, R2 = 0.82).CONCLUSION[18F]LW223 identifies a persistent and predominantly macrophage-driven inflammatory response with early [18F]LW223 infarct binding associated with later cardiac dysfunction.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"7 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1007/s00259-025-07705-1
Antonio Canosa, Stefano Callegaro, Umberto Manera, Rosario Vasta, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Francesca Palumbo, Barbara Iazzolino, Anastasia Dei Giudici, Enrico Matteoni, Grazia Zocco, Emilio Minerva, Alessandra Maccabeo, Giorgio Pellegrino, Daniela Pascariu, Maurizio Grassano, Pietro Piombino, Marcella Testa, Giulia Polverari, Giuseppe Fuda, Ilaria Merulla, Federico Casale, Salvatore Gallone, Cristina Moglia, Andrea Calvo, Marco Pagani, Adriano Chiò
Purpose Our aim was to investigate brain metabolic connectivity, as assessed via [ 18 F]FDG-PET, in ALS patients carrying the C9ORF72 expansion ( C9 -ALS). Methods We compared brain metabolism of C9 -ALS and patients without mutations of the main ALS-related genes (ctrl-ALS) through the two-sample t-test model of SPM12. Metabolic clusters showing a significant difference between the two groups were used as seed regions for an interregional correlation analysis (IRCA) in each group to evaluate metabolic connectivity. Results As compared to ctrl-ALS, C9 -ALS showed a relative hypometabolism in bilateral thalamus and left precentral and postcentral gyri, and a relative hypermetabolism in bilateral cerebellum and brainstem. In the IRCA, a positive correlation was found between the thalamic seed region and the cingulate cortex, including its anterior part. This correlation was broader in C9 -ALS than in Ctrl-ALS. A negative correlation between the thalamic seed region and the sensorimotor cortex was only found in C9 -ALS. In the IRCA, based on the cerebellar/brainstem cluster, positive correlations with the seed region substantially represented autocorrelation in both groups. Negative correlation, which mainly included frontal cortices, was more extensive in C9 -ALS than in Ctrl-ALS. Conclusion In the comparison with ctrl-ALS, C9 -ALS showed a relatively lower metabolism in the thalami and a relatively higher metabolism in the brainstem and the cerebellum. As compared to ctrl-ALS, C9 -ALS showed a predominant involvement of the salience network, which is related to cognitive and behavioural control. The cerebellum might be recruited to cope with cognitive impairment to a greater extent in C9 -ALS than in ctrl-ALS.
{"title":"Brain metabolic connectivity in ALS due to C9ORF72 hexanucleotide expansion: a [18F]FDG-PET study","authors":"Antonio Canosa, Stefano Callegaro, Umberto Manera, Rosario Vasta, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Francesca Palumbo, Barbara Iazzolino, Anastasia Dei Giudici, Enrico Matteoni, Grazia Zocco, Emilio Minerva, Alessandra Maccabeo, Giorgio Pellegrino, Daniela Pascariu, Maurizio Grassano, Pietro Piombino, Marcella Testa, Giulia Polverari, Giuseppe Fuda, Ilaria Merulla, Federico Casale, Salvatore Gallone, Cristina Moglia, Andrea Calvo, Marco Pagani, Adriano Chiò","doi":"10.1007/s00259-025-07705-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07705-1","url":null,"abstract":"Purpose Our aim was to investigate brain metabolic connectivity, as assessed via [ <jats:sup>18</jats:sup> F]FDG-PET, in ALS patients carrying the <jats:italic>C9ORF72</jats:italic> expansion ( <jats:italic>C9</jats:italic> -ALS). Methods We compared brain metabolism of <jats:italic>C9</jats:italic> -ALS and patients without mutations of the main ALS-related genes (ctrl-ALS) through the two-sample t-test model of SPM12. Metabolic clusters showing a significant difference between the two groups were used as seed regions for an interregional correlation analysis (IRCA) in each group to evaluate metabolic connectivity. Results As compared to ctrl-ALS, <jats:italic>C9</jats:italic> -ALS showed a relative hypometabolism in bilateral thalamus and left precentral and postcentral gyri, and a relative hypermetabolism in bilateral cerebellum and brainstem. In the IRCA, a positive correlation was found between the thalamic seed region and the cingulate cortex, including its anterior part. This correlation was broader in <jats:italic>C9</jats:italic> -ALS than in Ctrl-ALS. A negative correlation between the thalamic seed region and the sensorimotor cortex was only found in <jats:italic>C9</jats:italic> -ALS. In the IRCA, based on the cerebellar/brainstem cluster, positive correlations with the seed region substantially represented autocorrelation in both groups. Negative correlation, which mainly included frontal cortices, was more extensive in <jats:italic>C9</jats:italic> -ALS than in Ctrl-ALS. Conclusion In the comparison with ctrl-ALS, <jats:italic>C9</jats:italic> -ALS showed a relatively lower metabolism in the thalami and a relatively higher metabolism in the brainstem and the cerebellum. As compared to ctrl-ALS, <jats:italic>C9</jats:italic> -ALS showed a predominant involvement of the salience network, which is related to cognitive and behavioural control. The cerebellum might be recruited to cope with cognitive impairment to a greater extent in <jats:italic>C9</jats:italic> -ALS than in ctrl-ALS.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"33 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1007/s00259-025-07703-3
Jonathan Kuten, Stephanie Chahwan, Charlie White, Audrey Mauguen, Heiko Schöder, Simone Krebs
{"title":"Shining the PSMA spotlight on peritoneal metastases in prostate cancer","authors":"Jonathan Kuten, Stephanie Chahwan, Charlie White, Audrey Mauguen, Heiko Schöder, Simone Krebs","doi":"10.1007/s00259-025-07703-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07703-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1007/s00259-025-07697-y
Siqi Li,Yuxuan Liu,Jun Liu,Baojun Sang,Yanfeng Xu,Xiaorong Sun,Jigang Yang
PURPOSETo evaluate and compare the diagnostic performance of fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide (18F-AlF-NOTATATE) PET/CT and iodine-123 Metaiodobenzylguanidine (123I-MIBG) scintigraphy with SPECT/CT in detecting recurrent high-risk neuroblastoma (HR-NB) after complete response (CR), and to evaluate their impact on clinical decision-making.METHODSThis retrospective study included 68 HR-NB patients (67 with confirmed recurrences, 1 without recurrence) who underwent 18F-AlF-NOTATATE PET/CT and 123I-MIBG scintigraphy with SPECT/CT within 7 days. Imaging findings were analyzed for sensitivity, lesion patterns, anatomical locations, spatial distribution, and semiquantitative Curie scores. The impact on clinical management was evaluated by comparing actual versus hypothetical treatment decisions. Recurrence was confirmed using a composite reference standard (histopathology or ≥ 6-month of imaging/clinical follow-up).RESULTS18F-AlF-NOTATATE PET/CT demonstrated numerically higher sensitivity than 123I-MIBG scintigraphy with SPECT/CT (97.0% vs. 88.2%). The combined use of both modalities achieved 100% sensitivity, a statistically significant improvement over either single modality (p < 0.001). Recurrences predominantly exhibited focal/mixed patterns (94.0%) and distant metastases (82.0%; p < 0.001). 18F-AlF-NOTATATE PET/CT yielded significantly higher Curie scores (p = 0.002). Clinically, 18F-AlF-NOTATATE PET/CT influenced therapeutic decisions in 37.5% of cases, versus 5% for 123I-MIBG scintigraphy with SPECT/CT alone. Combined imaging affected management in 58.8% of cases (72.5% therapeutic shifts).CONCLUSION18F-AlF-NOTATATE PET/CT provides critical complementary value to 123I-MIBG scintigraphy with SPECT/CT. It provides a numerical sensitivity benefit, mitigates MIBG non-avidity limitations, and informs clinical decision-making. The combined use of both imaging modalities achieves 100% sensitivity, supporting the integration of this dual-modality approach into HR-NB surveillance protocols.
{"title":"Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.","authors":"Siqi Li,Yuxuan Liu,Jun Liu,Baojun Sang,Yanfeng Xu,Xiaorong Sun,Jigang Yang","doi":"10.1007/s00259-025-07697-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07697-y","url":null,"abstract":"PURPOSETo evaluate and compare the diagnostic performance of fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide (18F-AlF-NOTATATE) PET/CT and iodine-123 Metaiodobenzylguanidine (123I-MIBG) scintigraphy with SPECT/CT in detecting recurrent high-risk neuroblastoma (HR-NB) after complete response (CR), and to evaluate their impact on clinical decision-making.METHODSThis retrospective study included 68 HR-NB patients (67 with confirmed recurrences, 1 without recurrence) who underwent 18F-AlF-NOTATATE PET/CT and 123I-MIBG scintigraphy with SPECT/CT within 7 days. Imaging findings were analyzed for sensitivity, lesion patterns, anatomical locations, spatial distribution, and semiquantitative Curie scores. The impact on clinical management was evaluated by comparing actual versus hypothetical treatment decisions. Recurrence was confirmed using a composite reference standard (histopathology or ≥ 6-month of imaging/clinical follow-up).RESULTS18F-AlF-NOTATATE PET/CT demonstrated numerically higher sensitivity than 123I-MIBG scintigraphy with SPECT/CT (97.0% vs. 88.2%). The combined use of both modalities achieved 100% sensitivity, a statistically significant improvement over either single modality (p < 0.001). Recurrences predominantly exhibited focal/mixed patterns (94.0%) and distant metastases (82.0%; p < 0.001). 18F-AlF-NOTATATE PET/CT yielded significantly higher Curie scores (p = 0.002). Clinically, 18F-AlF-NOTATATE PET/CT influenced therapeutic decisions in 37.5% of cases, versus 5% for 123I-MIBG scintigraphy with SPECT/CT alone. Combined imaging affected management in 58.8% of cases (72.5% therapeutic shifts).CONCLUSION18F-AlF-NOTATATE PET/CT provides critical complementary value to 123I-MIBG scintigraphy with SPECT/CT. It provides a numerical sensitivity benefit, mitigates MIBG non-avidity limitations, and informs clinical decision-making. The combined use of both imaging modalities achieves 100% sensitivity, supporting the integration of this dual-modality approach into HR-NB surveillance protocols.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSEProstate-specific membrane antigen (PSMA) PET/CT enhances prostate cancer (PCa) diagnosis. The newly developed PSMA probe, [68Ga]Ga-P16-093, with low urinary excretion, has shown superior diagnostic efficacy compared to conventional PSMA probes. This study aims to assess the diagnostic efficacy and local-regional staging performance of [68Ga]Ga-P16-093 in PCa lesions of newly diagnosed patients, using histopathology as the gold standard for validation.METHODSThis prospective study enrolled newly diagnosed PCa patients (April 2022-November 2023). All patients underwent [68Ga]Ga-P16-093 PET imaging, and a subset also received [68Ga]Ga-PSMA-11 PET/CT within one week. Radical prostatectomy within two weeks post-PET provided complete pathological specimens from all patients. The diagnostic efficacy and locoregional staging performance of [68Ga]Ga-P16-093 were statistically compared with that of [68Ga]Ga-PSMA-11, using histopathology as the gold standard.RESULTSFifty-six treatment-naïve male patients (mean age 67 ± 6 years; range 52-77) were prospectively enrolled. A subgroup of 37 patients who underwent both [⁶⁸Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT was analyzed for direct comparison. [68Ga]Ga-P16-093 PET/CT demonstrated superior diagnostic performance in primary prostate cancer evaluation, with sensitivity of 74.44% (201/270, 95% CI: 68.38-80.50%), specificity of 96.26% (387/402, 95% CI: 94.39-98.15%), and accuracy of 87.50% (588/672, 95% CI: 85.05-89.95%). Compared with [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-P16-093 PET/CT showed higher tracer uptake, with SUVmax of 9.86 ± 6.82 vs. 6.74 ± 1.89 (P = 0.041), SUVmean of 5.81 ± 4.03 vs. 3.98 ± 1.04 (P = 0.037), and T/B ratio of 23.19 ± 17.51 vs. 16.04 ± 7.75 (P = 0.042). Additionally, ROC analysis revealed a significantly greater AUC for P16-093 (0.85 vs. 0.75, P < 0.05). Moreover, locoregional staging accuracy was higher at 59.46% (22/37) compared with 32.43% (12/37) for [68Ga]Ga-PSMA-11 PET/CT.CONCLUSION[68Ga]Ga-P16-093 PET/CT exhibits high diagnostic performance in the diagnosis of primary PCa and shows significant advantages in identifying local tumor segments. [68Ga]Ga-P16-093 may serve as an alternative to [68Ga]Ga-PSMA-11 in the future diagnosis of PCa.TRIAL REGISTRATIONClinicalTrials.gov, NCT05324332. Registered 04 March 2022. URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332.
{"title":"[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11.","authors":"Jiarou Wang,Linlin Li,Jingci Chen,Rongxi Wang,Jialin Xiang,Xingtong Peng,Yanwei Wang,Yaping Luo,Lin Zhu,Hank F Kung,Zhien Zhou,Yu Xiao,Zhaohui Zhu","doi":"10.1007/s00259-025-07687-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07687-0","url":null,"abstract":"PURPOSEProstate-specific membrane antigen (PSMA) PET/CT enhances prostate cancer (PCa) diagnosis. The newly developed PSMA probe, [68Ga]Ga-P16-093, with low urinary excretion, has shown superior diagnostic efficacy compared to conventional PSMA probes. This study aims to assess the diagnostic efficacy and local-regional staging performance of [68Ga]Ga-P16-093 in PCa lesions of newly diagnosed patients, using histopathology as the gold standard for validation.METHODSThis prospective study enrolled newly diagnosed PCa patients (April 2022-November 2023). All patients underwent [68Ga]Ga-P16-093 PET imaging, and a subset also received [68Ga]Ga-PSMA-11 PET/CT within one week. Radical prostatectomy within two weeks post-PET provided complete pathological specimens from all patients. The diagnostic efficacy and locoregional staging performance of [68Ga]Ga-P16-093 were statistically compared with that of [68Ga]Ga-PSMA-11, using histopathology as the gold standard.RESULTSFifty-six treatment-naïve male patients (mean age 67 ± 6 years; range 52-77) were prospectively enrolled. A subgroup of 37 patients who underwent both [⁶⁸Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT was analyzed for direct comparison. [68Ga]Ga-P16-093 PET/CT demonstrated superior diagnostic performance in primary prostate cancer evaluation, with sensitivity of 74.44% (201/270, 95% CI: 68.38-80.50%), specificity of 96.26% (387/402, 95% CI: 94.39-98.15%), and accuracy of 87.50% (588/672, 95% CI: 85.05-89.95%). Compared with [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-P16-093 PET/CT showed higher tracer uptake, with SUVmax of 9.86 ± 6.82 vs. 6.74 ± 1.89 (P = 0.041), SUVmean of 5.81 ± 4.03 vs. 3.98 ± 1.04 (P = 0.037), and T/B ratio of 23.19 ± 17.51 vs. 16.04 ± 7.75 (P = 0.042). Additionally, ROC analysis revealed a significantly greater AUC for P16-093 (0.85 vs. 0.75, P < 0.05). Moreover, locoregional staging accuracy was higher at 59.46% (22/37) compared with 32.43% (12/37) for [68Ga]Ga-PSMA-11 PET/CT.CONCLUSION[68Ga]Ga-P16-093 PET/CT exhibits high diagnostic performance in the diagnosis of primary PCa and shows significant advantages in identifying local tumor segments. [68Ga]Ga-P16-093 may serve as an alternative to [68Ga]Ga-PSMA-11 in the future diagnosis of PCa.TRIAL REGISTRATIONClinicalTrials.gov, NCT05324332. Registered 04 March 2022. URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"140 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09DOI: 10.1007/s00259-025-07699-w
Laura Evangelista, Carlo Vallone, Priscilla Guglielmo, Sara Damiani, Jelena Jandric, Andrea Brignoli, Manuela Marenco, Francesco Martino, Luciana Di Cristina, Ciro Franzese, Rosario Mazzola
{"title":"PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria?","authors":"Laura Evangelista, Carlo Vallone, Priscilla Guglielmo, Sara Damiani, Jelena Jandric, Andrea Brignoli, Manuela Marenco, Francesco Martino, Luciana Di Cristina, Ciro Franzese, Rosario Mazzola","doi":"10.1007/s00259-025-07699-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07699-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"20 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1007/s00259-025-07701-5
Jan Wuestemann,Elisabeth Eppard,Daniel Hescheler,Joanna Wybranska,Dennis Kupitz,Falco Reissig,Frankis G Almaguel,Akram Al-Ibraheem,Johannes Notni,Michael C Kreissl
{"title":"Radioligand therapy of pancreatic ductal adenocarcinoma using an αvβ6-integrin targeting 68Ga / 177Lu labeled theranostic pair.","authors":"Jan Wuestemann,Elisabeth Eppard,Daniel Hescheler,Joanna Wybranska,Dennis Kupitz,Falco Reissig,Frankis G Almaguel,Akram Al-Ibraheem,Johannes Notni,Michael C Kreissl","doi":"10.1007/s00259-025-07701-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07701-5","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"4 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1007/s00259-025-07698-x
Yan Zhang, Mei Xin, Cheng Wang, Zhoumi Hu, Yue Wang, Hongda Shao, Jianjun Liu, Chenpeng Zhang
{"title":"Correction to: Neuronal intranuclear inclusion disease with cerebellar white matter tau uptake and incidental meningioma","authors":"Yan Zhang, Mei Xin, Cheng Wang, Zhoumi Hu, Yue Wang, Hongda Shao, Jianjun Liu, Chenpeng Zhang","doi":"10.1007/s00259-025-07698-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07698-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"78 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145680145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：